Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

PEPTONIC Medical AB: Peptonic signs license agreement with Prima Lab regarding self-test for urinary tract infections

Lataa tiedote

PEPTONIC Medical AB announces that the company has signed a license agreement with Swiss medical technology company Prima Lab SA regarding self-tests for urinary tract infections for sale in Sweden.

The agreement means that Peptonic gets the right to sell Prima Lab's self-test for urinary tract infections under its own brand VagiVital[®] in Sweden, with a planned launch at the end of 2023.

"Urinary tract infections affect 40% of all women of all ages at some point in their lives, with many experiencing recurrent infections. Adding another high-quality self-test to the reference market Sweden will be another valuable step in building a leading portfolio of clinically proven self-care products consistent with the principle of diagnose, treat and prevent", says Erik Sundquist, CEO of Peptonic.

Prima Lab is a Swiss medical technology company with a specific focus on self-tests for women's health. The company conducts its own research and development and sells its products in more than thirty countries around the world. Prima Lab's self-test for urinary tract infections has a high level of precision as it measures on four parameters - blood, protein, leukocytes and nitrites - unlike most other products that measure only two or three parameters.

Prima Lab is already a strategic partner to Peptonic as Prima distributes Peptonics patented test for amniocentesis exclusively in a number of selected markets in Europe.

"To deepen the collaboration with Prima Lab, which is a leading player in self-tests for women's health, we see as a very valuable step as we continue to build our portfolio", says Erik Sundquist.

"Peptonic is a growing and important player in women's health. Accordingly, we see the introduction of our self-test for urinary tract infections on the Swedish market as very valuable for our continued expansion", says Prima Lab's CEO and founder Federico Roveda.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.